Knee Osteoarthritis (KOA) Research at Viswanathan Lab
The Viswanathan Lab has conducted Canada’s first mesenchymal stromal cell (MSC) trial in knee osteoarthritis (KOA) patients, and this paper received The Arthritis Society Canada’s Top 10 Research Achievements in 2019. Following up on the MSC clinical trial, we showed that heterogeneity in MSC donors can be prospectively identified (Robb et al) and three patents have been filed (US18/210,490, PCT/CA2025/050044, US19/488,476).
Using our 2019-2025 CIHR grant, we identified biomarkers to segregate responsive KOA patients (BioRxiv 1, In Revision, Stem Cell Reports). MSCs mechanism of action on macrophages through IL-6 was also investigated (BioRxiv 2, In Revision, Cell Death and Disease). We published in Nature and Cell Stem Cell reviews on MSCs in KOA. Using statistical and machine learning models, we are parsing MSC donor heterogeneity (Kolade et al., manuscript in prep 2025). Our work informs strategies to stratify KOA patients and reduce MSC donor heterogeneity— both key to achieving successful clinical outcomes and is thus applied knowledge. Dr. Viswanathan has presented this work broadly at international meetings.
Dr. Viswanathan's work and leadership in the MSC field has been recognized as has been scientific chair of the MSC Committee at the International Society for Cell and Gene Therapy since 2022 to 2026, and co-chair since 2020 to 2022. She co-chaired an invitational only virtual workshop focused on mechanisms of action of MSCs, which resulted in a last-authored publication that outlines an experimental roadmap to tackle key barriers to successful clinical and commercial translation. Dr. Viswanathan is also co-leading a follow-up, in-person workshop at the ISCT Annual Meeting in Dublin 2026.
In parallel, the Viswanathan Lab has been exploring the role of different macrophage and monocyte subsets in experimental OA models, using transgenic mice to fate map the embryonic and adult bone marrow origin of macrophages. We are also using tamoxifen inducible transgenic mice to temporally ablate specific macrophages, including long-lived, embryonically derived macrophage subsets to understand their roles during experimental OA. Single cell transcriptomics and epigenomics studies will allow us to better dissect functional roles of embryonically derived macrophages. Targets from these omics studies will be queried using knocked-down/over-expressing PSC-derived macrophages and will serve as the basis for adoptive transfer immunotherapy. The adoptive transfer approach won a Biologics Association’s Summit Research Award (2021); have given invited talks at The Macrophage Summit (2020, 2021 and 2022) and at PRIME Research Rounds (University of Toronto, 2024); partnered with a company (SRA #2023-0071) to develop this therapy. Additionally, endogenous programming of long-lived, embryonically derived, resident macrophages and adult, bone marrow-derived recruited macrophages is also being attempted using several different methods including probiotics, short chain fatty acids, and mitochondrial transplant. The Viswanathan Lab is also exploring mechanisms of monocyte/macrophage reprogramming including understanding histone modifications and how this impacts transcriptional, metabolic, and functional states of monocytes/macrophages.
Dr. Viswanathan co-developed in vitro joint-on-dish static explant tissue-based KOA, which was published in Osteoarthritis and Cartilage and cited as Top 10 2021 Research Advances by The Arthritis Society. Using this know-how, we have now developed a joint-specific psoriatic arthritis (PsA) model with Dr. Vinod Chandran as a research tool to study patient-specific responses to current PsA treatments. The OA explant model has also been converted to a joint-on-a-chip (JOC), incorporating microfluidics to simulate vascularized synovium and infiltration by monocytes with collaborator Dr. Edmond Young. These models are useful research tools and allow us to mechanistically study the role of synovium monocytes/macrophages in KOA.
Translational Clinical Research
This is a mature program that harnesses Dr. Viswanathan's years of experience in industry from Johnson and Johnson Regenerative Therapeutics between 2005-2009 developing regenerative medicine products, and her tenure as Associate Director of the UHN Cell Therapy Program from 2009 to 2015, where she enabled over 10 investigator-initiated and industry-led clinical trials. These include cardiac disease (Noiseux et al.), lysosomal storage disorder (Rupar et al.), and multiple myeloma (Williams et al.).
Leveraging these years of experience, Dr. Viswanathan secured $6.1M as PI from the Walter Schroeder Foundation. With Co-PI, Dr. Christopher Kim, a new Schroeder Arthritis Advanced Therapeutics Centre (SAATC) was established. As Sponsor-Principal Investigator, she has put together a multi-disciplinary team that is currently enrolling patients in a double-blinded, Health Canada-authorized, randomized control trial to evaluate autologous cellular therapies to test patient responsiveness based on patient baseline immunophenotype. This trial received competitive peer-reviewed funding from Stem Cell Network’s clinical trials award program, highlighting the critical knowledge gap in level 1 evidence for using biologics injections in KOA. LEAP IN BIO (Longitudinal Evaluation of Arthritis Patients with Injectable Biologics), a 400 knee and shoulder OA patient is also underway (REB# 21-6226) and will similarly evaluate baseline immune profiles to identify responders. Both studies will be impactful in providing high level evidence for the use of injectable biologics and identify a subset of patients who may be responsive, potentially altering clinical practice.